Navigation Links
SEI Defined Benefit Client Recognized With Leading Plan Design Award
Date:10/14/2009

OAKS, Pa., Oct. 14 /PRNewswire-FirstCall/ -- SEI (Nasdaq: SEIC) today announced that one of the company's institutional clients -- Meda Pharmaceuticals -- was recognized with the "Solutions Superstar" award by EmployersWeb. The award honors Meda for their outstanding and innovative defined benefit plan management including asset allocation changes and strategies aimed at matching the duration of invested assets with the plan's liabilities.

The Solutions Superstar for Most Innovative Plan Design from EmployersWeb.com recognizes the strongest examples within corporate America of excellent plan design management. Meda was honored with the award, in part, because it successfully met its goal of providing stability and predictability to its plan contributions. The company implemented a dynamic investment management strategy designed to proactively evaluate asset allocations and utilize investment products aligned with their organizational goal of minimizing contribution volatility.

"Meda Pharmaceutical's pension and finance professionals should be commended for their strategic decision-making," said Roger Messina, Vice President and Managing Director, Relationship Management for SEI's Institutional Group. "Their vision for creating stability in their defined benefit pension plan is a model for others to follow. SEI is proud to partner with Meda in helping improve their financial management of the plan and we applaud their efforts."

For more information about the Solutions Superstars Awards, please visit www.employersweb.com.

About SEI's Institutional Group

SEI's Institutional Group delivers integrated healthcare, retirement and nonprofit investment solutions to over 500 global institutional clients (of which 340 are U.S. based) in six different countries. SEI enables clients to meet financial objectives, reduce business risk, and fulfill their due diligence requirements through implemented fiduciary management strategies for defined benefit plans, defined contribution plans, endowments, foundations and other balance sheet assets. For more information, visit www.seic.com/institutions.

About SEI

SEI (Nasdaq:SEIC) is a leading global provider of outsourced asset management, investment processing and investment operations solutions. The company's innovative solutions help corporations, financial institutions, financial advisors, and affluent families create and manage wealth. As of June 30, 2009, through its subsidiaries and partnerships in which the company has a significant interest, SEI administers $360 billion in mutual fund and pooled assets and manages $136 billion in assets. SEI serves clients, conducts or is registered to conduct business and/or operations, from numerous offices worldwide. For more information, visit www.seic.com.

SOURCE SEI


'/>"/>
SOURCE SEI
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. URAC Introduces New Performance Measures and Reporting Standards for Pharmacy Benefit Management and Drug Therapy Management Accreditation
2. Urologists, Radiologists, Patients Benefit From New Clinical Prostate Visualization System
3. Anemic Patients With MDS Gain Long-Term Benefits From Erythropoietin and Myeloid Growth Factor Hormones
4. Yoga Benefits Back-Pain Patients
5. New Assessment Quantifies Risks and Benefits of Warfarin Treatment for Atrial Fibrillation
6. Teeth and Gums Also Benefit from the Healing Power of Aloe Vera
7. Glybera(TM) Shows Long-Term Health Benefits
8. Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
9. MitraClip(R) Therapy Data Demonstrate Clinical Benefit in High-Risk Patients With Mitral Regurgitation
10. New MADIT II Clinical Data Analysis Shows Long-Term Survival Benefit for Implantable Defibrillator Therapy
11. New Body of Research Suggests Statin Use Benefits Multiple Areas of Urologic Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... LONDON , February 10, 2016 A new report ... 2021 - states that the Alzheimer,s disease market will more than double ... 2021, at a Compound Annual Growth Rate (CAGR) of 11%. ... Italy , Spain , the UK, and ... prevalence during the forecast period. --> Canada , ...
(Date:2/10/2016)... SAN DIEGO , Feb. 10, 2016 ... viral gene therapy manufacturing, and Renova™ Therapeutics, a biopharmaceutical ... and other chronic diseases, have entered into a Manufacturing ... produce cGMP-grade RT-100 (Ad5.hAC6) Drug Product for use in ... --> This relationship will leverage Lonza,s ...
(Date:2/10/2016)... , Feb. 10, 2016 Immune Pharmaceuticals Inc. ... announced today that it has filed a patent application ... other cancers. --> --> ... by administration of Ceplene (histamine dihydrochloride) in combination with ... of predicting the efficacy of Ceplene and IL-2 therapy ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Intermedix ... of Emergency Medicine , an emergency medicine professional association, to support the organization's ... , The American Academy of Emergency Medicine, or AAEM, seeks to empower emergency ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Emergency rooms provide ... to find. Unfortunately, this can leave patients with dental emergencies at risk of losing ... now offering emergency dental care. , Common dental emergencies include:, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Jessica Barron, of ... is now accepting new dental patients and families in the North Metro Denver area. ... services from cleanings to cosmetic dentistry, and all in the most relaxing environment. , ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... organization, welcomes S.S. Nesbitt as the latest addition to its growing list of ... other locations throughout the Southeast, from Orlando to Huntsville and in between. , ...
(Date:2/10/2016)... ... , ... Armune BioScience signed a definitive agreement with ARCpoint ... across the country. Launched in April of 2015, Apifiny is the only cancer specific, ... order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized ...
Breaking Medicine News(10 mins):